Sigrima 420mg Injection
Marketer
Zydus Lifesciences Ltd
Salt Composition
Pertuzumab (420mg)
Overview Sigrima 420mg Injection
Oncaspar 420mg injection is a monoclonal antibody medication indicated for the treatment of breast cancer. Administered intravenously under medical supervision, the dosage and frequency are determined by your physician based on individual needs and may vary. Adhere strictly to the prescribed regimen; incorrect usage or overdose can lead to severe adverse reactions. Therapeutic benefits may not be immediately apparent, potentially requiring weeks or months; discontinue use only upon your doctor's instruction. Common side effects include alopecia, nausea, diarrhea, and lassitude. This medication can reduce blood cell counts (specifically white blood cells), increasing infection risk. Regular blood tests to monitor blood cell levels, along with cardiac, hepatic, and renal function, are essential. Inform your healthcare provider of all other medications you are taking, as interactions may occur. This medication is contraindicated during pregnancy and lactation; effective contraception for both partners is crucial throughout the treatment period.
Primary Ingredients of Sigrima 420mg Injection
No information provided. Please provide the text you wish me to rephrase.
Uses of Sigrima 420mg Injection
Malignant breast tumor
Major Benefits of Sigrima 420mg Injection:
This medication will be administered by your healthcare provider. Self-medication is strictly prohibited.
Common Side effects of Sigrima 420mg Injection:
- Diarrhea
- Hair loss
- Feeling sick
- Rash
- Stomach inflammation
- Decreased blood cells (red cells, white cells, and platelets)
- Muscle pain
- Cough
- Heartburn
- Breathlessness
- Dizziness
- Fatigue
How to use Sigrima 420mg Injection:
This medication will be administered by your healthcare provider. Self-medication is strongly discouraged.
How Sigrima 420mg Injection works:
The injectable monoclonal antibody, Sigrima 420mg, targets and binds to particular proteins expressed on the surface of malignant cells. By binding to the human epidermal growth factor receptor 2 (HER2), Sigrima 420mg Injection can inhibit or eliminate cancerous cell proliferation.
SAFETY ADVICE
AlcoholCONSULT YOUR DOCTOR
Alcohol consumption alongside Sigrima 420mg Injection may pose unknown risks. Seek medical advice before combining them.
PregnancyCONSULT YOUR DOCTOR
Administering Sigrima 420mg Injection during pregnancy is contraindicated due to established harm to the fetus. Exceptionally, a physician might consider its use in critical circumstances where potential advantages outweigh the known risks. Physician consultation is mandatory.
Breast feedingUNSAFE
Administering Sigrima 420mg Injection while breastfeeding is contraindicated. Evidence indicates potential infant toxicity from this medication.
DrivingCONSULT YOUR DOCTOR
The impact of a 420mg Sigrima Injection on driving ability is undetermined. Refrain from operating a vehicle if you develop symptoms impairing concentration or reaction time.
KidneySAFE IF PRESCRIBED
Sigrima 420mg Injection presents no need for dosage modification in patients with renal impairment and is considered safe for their use.
LiverCONSULT YOUR DOCTOR
Insufficient data exists regarding the administration of Sigrima 420mg Injection to individuals with hepatic impairment. Physician consultation is advised.
What if you forget to take Sigrima 420mg Injection :
NA
Facts to Know About Sigrima 420mg Injection
| Label | Value |
|---|---|
| Chemical Type | Monoclonal antibody |
| Developing Habits | No. |
| Type of Therapy | Cancer Medications |
| Behavior Class | Monoclonal Antibody HER2/neu (ErbB2) Inhibitor |
3,018 People bought this recently